FY2026 Earnings Estimate for VYGR Issued By Leerink Partnrs

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at Leerink Partnrs dropped their FY2026 EPS estimates for Voyager Therapeutics in a report issued on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings per share of ($0.62) for the year, down from their prior estimate of ($0.49). The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ FY2027 earnings at ($1.36) EPS.

Several other analysts have also commented on VYGR. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group lowered their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.97.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $3.16 on Friday. The business has a fifty day moving average price of $3.76 and a 200 day moving average price of $5.32. Voyager Therapeutics has a 1-year low of $2.75 and a 1-year high of $9.55. The stock has a market capitalization of $174.45 million, a P/E ratio of 4.45 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same quarter in the prior year, the company earned $1.25 EPS.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Voyager Therapeutics in the fourth quarter worth approximately $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares during the last quarter. Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics in the 4th quarter valued at $60,000. Finally, Tema Etfs LLC purchased a new stake in Voyager Therapeutics in the 4th quarter valued at $85,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.